NCT00791752View on ClinicalTrials.gov

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2008

Study Completion Date

March 31, 2009

Conditions
Healthy
Interventions
DRUG

AZD4017

ascending single doses (start dose 2 mg), oral suspension

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Research Site, Gotteborg

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY